Amryt Pharma PLC - commercial-stage biopharmaceutical company - Signs a distribution agreement with Medison Pharma Canada to distribute Myalepta in Canada. This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept and Lojuxta in Israel, and Juxtapid in Canada.
"Today's announcement represents continued progress as we grow our commercial assets and expand access to treatment for patients in existing and new territories. We are also pleased to extend our engagement with Medison and further benefit from their expertise in Canada and other territories," says Amryt Chief Executive Joe Wiley.
Current stock price: 196.75 pence
Year-to-date change: up 6.1%
By Evelina Grecenko; firstname.lastname@example.org
Copyright 2021 Alliance News Limited. All Rights Reserved.